Back to Search
Start Over
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
- Source :
- Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
- Publication Year :
- 2022
- Publisher :
- Nature Portfolio, 2022.
-
Abstract
- Limited response to immune checkpoint inhibitors has been reported in patients with castration-resistant prostate cancer. Here the authors show that intermittent, but not continuous, treatment with an anti-PI3Kα/β/δ-inhibitor promotes anti-tumor immunity and response to PD-1 blockade in a preclinical Pten-null model of prostate cancer.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 13
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.10d0bcbff27a44d084d7bcd464438339
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-021-27833-0